[go: up one dir, main page]

PL1663194T3 - Zastosowanie SAHA do leczenia międzybłoniaka - Google Patents

Zastosowanie SAHA do leczenia międzybłoniaka

Info

Publication number
PL1663194T3
PL1663194T3 PL04782425T PL04782425T PL1663194T3 PL 1663194 T3 PL1663194 T3 PL 1663194T3 PL 04782425 T PL04782425 T PL 04782425T PL 04782425 T PL04782425 T PL 04782425T PL 1663194 T3 PL1663194 T3 PL 1663194T3
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
present
mesothelioma
saha
methods
Prior art date
Application number
PL04782425T
Other languages
English (en)
Inventor
Nicholas G Bacopoulos
Judy H Chiao
Thomas A Miller
Carolyn M Paradise
Victoria M Richon
Original Assignee
Merck Hdac Res Llc
Sloan Kettering Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/650,025 external-priority patent/US7148257B2/en
Priority claimed from US10/665,079 external-priority patent/US20040127523A1/en
Application filed by Merck Hdac Res Llc, Sloan Kettering Inst Cancer Res filed Critical Merck Hdac Res Llc
Publication of PL1663194T3 publication Critical patent/PL1663194T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Steroid Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Electrotherapy Devices (AREA)
PL04782425T 2003-08-26 2004-08-26 Zastosowanie SAHA do leczenia międzybłoniaka PL1663194T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/650,025 US7148257B2 (en) 2002-03-04 2003-08-26 Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US10/665,079 US20040127523A1 (en) 2002-03-04 2003-09-16 Methods of treating cancer with HDAC inhibitors
PCT/US2004/027943 WO2005018578A2 (en) 2003-08-26 2004-08-26 Method of treating cancer with hdac inhibitors
EP04782425A EP1663194B1 (en) 2003-08-26 2004-08-26 Use of SAHA for treating mesothelioma

Publications (1)

Publication Number Publication Date
PL1663194T3 true PL1663194T3 (pl) 2011-01-31

Family

ID=34556614

Family Applications (2)

Application Number Title Priority Date Filing Date
PL379887A PL379887A1 (pl) 2003-08-26 2004-08-26 Sposób leczenia raka inhibitorami HDAC
PL04782425T PL1663194T3 (pl) 2003-08-26 2004-08-26 Zastosowanie SAHA do leczenia międzybłoniaka

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL379887A PL379887A1 (pl) 2003-08-26 2004-08-26 Sposób leczenia raka inhibitorami HDAC

Country Status (23)

Country Link
US (1) US20090012175A1 (pl)
EP (2) EP1663194B1 (pl)
JP (2) JP4338734B2 (pl)
KR (1) KR100924737B1 (pl)
CN (1) CN102188415A (pl)
AT (1) ATE462426T1 (pl)
AU (1) AU2004266169B9 (pl)
BR (1) BRPI0413826A (pl)
CA (1) CA2535806C (pl)
DE (1) DE602004026321D1 (pl)
DK (1) DK1663194T3 (pl)
EC (1) ECSP066452A (pl)
ES (1) ES2345775T3 (pl)
HR (1) HRP20060080A2 (pl)
IL (1) IL173846A0 (pl)
MA (1) MA28209A1 (pl)
NO (1) NO328575B1 (pl)
NZ (2) NZ560485A (pl)
PL (2) PL379887A1 (pl)
PT (1) PT1663194E (pl)
RU (1) RU2356547C2 (pl)
SI (1) SI1663194T1 (pl)
WO (1) WO2005018578A2 (pl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
CN1720034A (zh) * 2002-03-04 2006-01-11 艾顿药物公司 诱导末期分化的方法
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
CA2520611A1 (en) 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
US7901675B2 (en) * 2004-10-13 2011-03-08 U.S. Department Of Veterans Affairs Method of using coenzyme Q10 to treat Huntington's disease
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
NZ599464A (en) 2005-02-03 2014-03-28 Topotarget Uk Ltd Combination therapies using hdac inhibitors
EP1861126A4 (en) 2005-03-22 2009-11-18 Harvard College TREATMENT OF PROTEIN REMOVAL TROUBLES
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
WO2006122319A2 (en) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
PT1901729E (pt) * 2005-05-13 2012-04-30 Topotarget Uk Ltd Formulações farmacêuticas de inibidores de hdac
TWI415603B (zh) 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
KR20080032188A (ko) 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
GB0518720D0 (en) * 2005-09-14 2005-10-19 Hamlet Pharma Ab Therapeutic combination
CN101299921A (zh) * 2005-11-04 2008-11-05 默克公司 用saha和硼替佐米治疗癌症的方法
AU2006311829B8 (en) * 2005-11-04 2013-02-21 Merck Sharp & Dohme Corp. Methods of treating cancers with SAHA, Carboplatin, and Paclitaxel and other combination therapies
WO2007056243A2 (en) * 2005-11-04 2007-05-18 Merck & Co. Inc. Methods of treating cancers with saha and fluorouracil and other combination therapies
US8828392B2 (en) * 2005-11-10 2014-09-09 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
CA2642273C (en) 2006-02-14 2016-09-20 President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
PL2010168T3 (pl) 2006-02-14 2014-09-30 The President And Fellows Of Harvard College Inhibitory deacetylazy histonowej
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
WO2007130429A2 (en) 2006-05-03 2007-11-15 The President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
WO2008053131A1 (en) 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
WO2008057456A2 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
AU2007342028B2 (en) 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
MX2010003230A (es) * 2007-09-25 2010-04-07 Topotarget Uk Ltd Metodos para la sintesis de ciertos compuestos de acido hidroxamico.
WO2009064300A1 (en) * 2007-11-15 2009-05-22 The Johns Hopkins University Combinations of hdac inhibitors and cytokines/growth factors
MX2010009642A (es) * 2008-03-07 2010-09-22 Topotarget As Metodos de tratamiento utilizando infusion continua prolongada de belinostat.
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
CA2740559C (en) 2008-10-15 2016-02-16 Generics [Uk] Limited Improved process
CA2744448A1 (en) 2008-11-26 2010-06-03 Vinayak Gore Polymorphs
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
CA2804795A1 (en) 2010-07-12 2012-01-19 Nicholas Vrolijk Romidepsin solid forms and uses thereof
CN103261890B (zh) * 2010-09-10 2016-04-06 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CN102846611A (zh) * 2011-09-24 2013-01-02 复旦大学 斯克瑞泰Scriptaid在制备治疗创伤性脑损伤疾病药物中的用途
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
CA2888021A1 (en) 2012-10-15 2014-04-24 Epizyme, Inc. Substituted n-((2-oxo-1,2-dihydropyridin-3-yl)-methyl)-benzamide compounds and their use in the treatment of ezh2-mediated disorders
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
CN103169807A (zh) * 2013-04-11 2013-06-26 太仓市胜舟生物技术有限公司 一种中西组合药物在制药中的应用
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
WO2015190700A1 (ko) * 2014-06-11 2015-12-17 성균관대학교산학협력단 패혈증 예방 또는 치료용 약학적 조성물
CN111195249B (zh) * 2018-11-20 2023-11-28 深圳微芯生物科技股份有限公司 西达本胺联合r-chop的应用及联合药物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
CA2231251A1 (en) 1995-09-20 1997-03-27 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
AUPP505798A0 (en) 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
US6656905B1 (en) 1998-10-13 2003-12-02 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide compound and use thereof
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
CN1378450A (zh) 1999-09-08 2002-11-06 斯隆-凯特林癌症研究院 新型细胞分化剂和组蛋白脱乙酰基酶抑制剂及其使用方法
EP1748046A3 (en) 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
US7288567B2 (en) 2000-03-24 2007-10-30 Methylgene Inc. Inhibitors of histone deacetylase
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2001287157A1 (en) * 2000-09-12 2002-03-26 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
AU2002318364A1 (en) * 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Novel human histone deacetylases
ITMI20011733A1 (it) * 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
WO2003070188A2 (en) * 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
CN1720034A (zh) * 2002-03-04 2006-01-11 艾顿药物公司 诱导末期分化的方法
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
EP1567142A4 (en) * 2002-11-20 2005-12-14 Errant Gene Therapeutics Llc TREATMENT OF PULMONARY CELLS WITH HISTONE DEACETYLASE INHIBITORS
CA2520611A1 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis

Also Published As

Publication number Publication date
NZ560485A (en) 2009-03-31
DE602004026321D1 (de) 2010-05-12
DK1663194T3 (da) 2010-07-19
AU2004266169B9 (en) 2007-05-10
NO20061348L (no) 2006-05-23
WO2005018578A3 (en) 2005-05-12
JP4914411B2 (ja) 2012-04-11
EP1663194A2 (en) 2006-06-07
CN102188415A (zh) 2011-09-21
NZ545935A (en) 2009-02-28
NO328575B1 (no) 2010-03-22
ECSP066452A (es) 2006-09-18
PL379887A1 (pl) 2006-11-27
EP1663194B1 (en) 2010-03-31
EP1663194A4 (en) 2007-09-19
ES2345775T3 (es) 2010-10-01
HRP20060080A2 (en) 2006-07-31
JP2009073834A (ja) 2009-04-09
KR100924737B1 (ko) 2009-11-04
AU2004266169A2 (en) 2006-04-06
ATE462426T1 (de) 2010-04-15
IL173846A0 (en) 2006-07-05
WO2005018578A2 (en) 2005-03-03
RU2356547C2 (ru) 2009-05-27
RU2006109467A (ru) 2007-10-10
US20090012175A1 (en) 2009-01-08
SI1663194T1 (sl) 2010-08-31
KR20070029617A (ko) 2007-03-14
JP4338734B2 (ja) 2009-10-07
BRPI0413826A (pt) 2006-10-24
EP2201947A2 (en) 2010-06-30
EP2201947A3 (en) 2010-08-11
CA2535806A1 (en) 2005-03-03
AU2004266169B2 (en) 2007-05-03
CA2535806C (en) 2009-02-17
JP2007518694A (ja) 2007-07-12
AU2004266169A1 (en) 2005-03-03
MA28209A1 (fr) 2006-10-02
PT1663194E (pt) 2010-07-06

Similar Documents

Publication Publication Date Title
SI1663194T1 (sl) Uporaba SAHA za zdravljenje mezotelioma
WO2005039498A3 (en) Methods of treating cancer with hdac inhibitors
WO2003075839A3 (en) Methods of inducing terminal differentiation
EP1961748A3 (en) 2-Hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors
TW200510375A (en) New compounds
MXPA05008838A (es) Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht.
PL369108A1 (pl) Inhibitory dehydrogenazy 17 beta-hydroksysteroidowej typu 3 do leczenia chorób zależnych od androgenu
PL370292A1 (pl) Preparaty
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
IL179718A0 (en) Pharmaceutical composition containing irbesartan
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
MX2009008463A (es) Formulaciones biodisponibles de compuestos heterociclicos.
CY1110659T1 (el) Χρησιμοποιηση toy saha για την θεραπευτικη αγωγη μεσοθηλιωματος
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
MXPA04004907A (es) Composiciones de acetaminofen.
NO20024673D0 (no) Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin
EA200600998A1 (ru) Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза
TW200509902A (en) Pharmaceutical formulation for the treatment of overactive bladder
SE0203817D0 (sv) New composition
TW200728296A (en) Chemical compounds
WO2006121857A3 (en) Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses
UA54880C2 (uk) Застосування (s)-2-аміно-5-гуанідинопентанової кислоти (s)-2-аміноглутарату (l-аргініну l-глутамат) як фармацевтичного препарату, що має гепатопротекторну та детоксикуючу дію, спосіб його одержання, фармацевтична композиція на його основі